Addex' ADX10059 has potential for Parkinson's disease levodopa
induced dyskinesia (PD-LID)
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Français (PDF)Deutsch (PDF)English (PDF)Geneva, Switzerland, 14 September 2009 - Allosteric modulationcompany Addex Pharmaceuticals (SIX:ADXN) reported today that its leadproduct, ADX10059, which is nearing completion of Phase IIb testingin gastroesophageal reflux disease (GERD) and migraine prevention,also has demonstrated significant potential in a non-human primatemodel of Parkinson's disease levodopa induced dyskinesia (PD-LID).ADX10059 is an allosteric inhibitor - a negative allosteric modulator(NAM) - of a glutamate receptor subtype called metabotropic glutamatereceptor 5 (mGluR5). Phase IIb data are expected in the fourthquarter of 2009 for GERD (e.g. heartburn) and the first quarter of2010 for migraine prevention.In a recently completed study using the "MPTP" primate model, alldoses of ADX10059 abolished levodopa induced dyskinesia in the firsthour after levodopa administration. There was no adverse effect onParkinsonian disability scoring. The 10mg/kg and 30mg/kg doses ofADX10059 significantly reduced dyskinesia (p<0.05) in the first twohours after levodopa dosing.Addex also reported during its July R&D Day that in rats ADX10059showed a dose dependent effect in reducing catalepsy induced byhaloperidol, a rodent model of Parkinson's disease.PD-LID currently has no approved therapy. It is a complication causedby dopamine replacement (i.e. levodopa)therapy and characterized by a variety of hyperkinetic movements.Most PD patients develop LID after receiving levodopa for severalyears. Currently there are an estimated 1.2 million patients withPD-LID in the U.S. PD is a degenerative disease of the brain thatoften impairs motor skills, speech, and other functions. It isestimated that 60,000 new cases are diagnosed each year in the U.S.,where more than 1.5 million people currently have PD. While thecondition usually develops after the age of 65, 15% of thosediagnosed are under 50. PD affects both men and women in almost equalnumbers.The rationale for using mGluR5 inhibition in PD is as follows. Animbalance of neurotransmitters resulting from the loss of dopamineproducing cells leads to excess glutamatergic stimulation in thestriatopallidal pathway. Inhibition of glutamate stimulation in thispathway is believed be important for anti-Parkinsonian effects.mGluR5 are found abundantly in the striatum and are implicated in theexcess glutamate activity in Parkinson's Disease. Blockade of mGluR5has been shown to have anti-PD effects in a variety of animal models.Data from Addex and other researchers show that mGluR5 inhibition hastherapeutic potential in multiple indications. Addex has prioritizeddevelopment in GERD and migraine; others are pursuing PD-LID, FragileX syndrome and neuropathic pain.Addex Pharmaceuticals (www.addexpharma.com) discovers and developsallosteric modulators for human health. Allosteric modulators are adifferent kind of orally available small molecule therapeutic agent,which we believe will offer a competitive advantage over classicaldrugs. Our lead allosteric modulator product, ADX10059, has achievedclinical proof of concept and is in Phase IIb testing for thetreatment of GERD and, separately, migraine headache. ADX10059 is afirst-in-class mGluR5 inhibitor, a therapeutic strategy that also isbeing pursued in multiple indications by large pharma competitors.Our products and technology already have proven their value throughour relationships with four of the top 10 pharmaceutical companies inthe world. Specifically, under an agreement with Ortho-McNeil-JanssenInc., a Johnson & Johnson company, ADX71149, a positive allostericmodulator (PAM) of mGluR2, is undergoing Phase I clinical testing andhas potential for treatment of schizophrenia and anxiety. Under twoseparate agreements with Merck & Co., Inc., we are developing PAMs ofmGluR4 and mGluR5 as drugs to treat Parkinson's disease andschizophrenia, respectively. In addition, GlaxoSmithKline and Rochehave made equity investments in Addex.Chris MaggosHead of IR & CommunicationsAddex Pharmaceuticals+41 22 884 15 11chris.maggos(at)addexpharma.comDisclaimerThe foregoing release may contain forward-looking statements that canbe identified by terminology such as "not approvable", "continue","believes", "believe", "will", "remained open to exploring", "would","could", or similar expressions, or by express or implied discussionsregarding Addex Pharmaceuticals Ltd, its business, the potentialapproval of its products by regulatory authorities, or regardingpotential future revenues from such products. Such forward-lookingstatements reflect the current views of Addex Pharmaceuticals Ltdregarding future events, future economic performance or prospects,and, by their very nature, involve inherent risks and uncertainties,both general and specific, whether known or unknown, and/or any otherfactor that may materially differ from the plans, objectives,expectations, estimates and intentions expressed or implied in suchforward-looking statements. Such may in particular cause actualresults with allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7or other therapeutic targets to be materially different from anyfuture results, performance or achievements expressed or implied bysuch statements. There can be no guarantee that allosteric modulatorsof mGluR2, mGluR4, mGluR5, mGluR7 will be approved for sale in anymarket or by any regulatory authority. Nor can there be any guaranteethat allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 or othertherapeutic targets will achieve any particular levels of revenue (ifany) in the future. In particular, management's expectationsregarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 orother therapeutic targets could be affected by, among other things,unexpected actions by our partners, unexpected regulatory actions ordelays or government regulation generally; unexpected clinical trialresults, including unexpected new clinical data and unexpectedadditional analysis of existing clinical data; competition ingeneral; government, industry and general public pricing pressures;the company's ability to obtain or maintain patent or otherproprietary intellectual property protection. Should one or more ofthese risks or uncertainties materialize, or should underlyingassumptions prove incorrect, actual results may vary materially fromthose anticipated, believed, estimated or expected. AddexPharmaceuticals Ltd is providing the information in this pressrelease as of this date and does not undertake any obligation toupdate any forward-looking statements contained in this press releaseas a result of new information, future events or otherwise, except asmay be required by applicable laws.http://hugin.info/138017/R/1341036/320633.pdfhttp://hugin.info/138017/R/1341036/320634.pdfhttp://hugin.info/138017/R/1341036/320635.pdf --- End of Message ---Addex Pharmaceuticals12, chemin des Aulx Plan-les-Ouates, Geneva SwitzerlandISIN: CH0029850754; Index: SLIFE, SPI, SPIEX, SSCI;Listed: Main Market in SIX Swiss Exchange;
Datum: 14.09.2009 - 07:00 Uhr
Sprache: Deutsch
News-ID 5744
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 559 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex' ADX10059 has potential for Parkinson's disease levodopa
induced dyskinesia (PD-LID)"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
